论文部分内容阅读
肿瘤免疫导向治疗中与抗癌药物、放射性核素偶连的载体单克隆抗体 (monoclonal antibody ,Mc Ab)的异源性问题是束缚肿瘤免疫导向治疗临床应用的主要障碍 ,异源 Mc Ab的人源化改造是肿瘤免疫导向治疗研究的重点和难点[1 ] 。目前 ,抗视网膜母细胞瘤 (retinoblastoma,RB) Mc Ab?
Heterogeneity of the carrier monoclonal antibody (McAb) coupled with anticancer drugs and radionuclides in tumor immune-directed therapy is a major obstacle in the clinical application of immunotherapy directed at tumors. Heterologous Mc Ab Source of transformation is the focus of tumor immune-oriented research and difficult [1]. Currently, anti-retinoblastoma (RB) Mc Ab?